Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

ACCESSWIRE · Lexaria Bioscience Corp.

In This Article:

KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss.

On March 2, 2023 and June 16, 2023 Lexaria announced that in pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following:

  • Lowered blood glucose levels by 19.9% (p<0.05)

  • Lowered overall body weight by 7% sustained over 8 weeks

  • Witnessed a statistically significant increase in locomotor activity (p<0.05)

  • Lowered triglyceride levels by more than 25% (p<0.007)

  • Lowered blood urea nitrogen levels by 27.9% (p<0.001)

As a result of the very successful pre-clinical results, management of Lexaria has determined it is planning to undertake a human diabetes clinical study to investigate whether any of these improvements are also evidenced in humans. Study design is currently underway by Lexaria, which will be followed by submission to an independent review board to gain necessary approvals.

Lexaria intends to conduct the study at the same medical research hospital in Europe that it has utilized for its recent human clinical hypertension studies, subject to a number of conditions. This cost-effective approach allows Lexaria to complete the most research possible at a fraction of the cost of US-based registered study programs. Additional information including timelines and study details will be released when available.

DehydraTECH-CBD's ability to reduce blood sugar levels in animals is extremely encouraging and warrants additional investigation. According to the Center for Disease Control, managing your blood sugar levels is important to avoid diabetes-related conditions such as vision loss, heart disease, and kidney disease. Limited research, mostly in animal studies, indicates that generic CBD might be ineffective in controlling blood sugars. Using a similar formulation to that used in the pre-clinical animal study, the Company is very interested in discovering whether DehydraTECH-CBD might be effective in blood-sugar control in humans. It is hoped this research will help determine the potential of DehydraTECH-CBD for the treatment of diabetes and its complications.

About DehydraTECH

DehydraTECH is a patented drug delivery formulation and processing platform technology Lexaria has developed and is investigating for a variety of beneficial molecules. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bio-absorption when administered intraorally and topically.

Waiting for permission
Allow microphone access to enable voice search

Try again.